HenningCSroczynskiGHallssonLJahnBSiebertUMühlbergerN.Life expectancy predicted by decision-analytic models evaluating screening for prostate, lung, breast, and colorectal cancer: a systematic review focusing on competing mortality risks. Med Decis Making. 2025;45(8):927–50. DOI: 10.1177/0272989X251351613
2.
PenstonJ.Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? Yes. BMJ. 2011;343:d6395. DOI: 10.1136/bmj.d63
3.
TakahashiT.Evidence and rationale for prostate cancer screening. Prostate. 2025;85(13):1245–7. DOI: 10.1002/pros.70002
4.
TakahashiT.Prostate cancer screening: clinical trial rather than evidence-based medical practice. Eur J Clin Invest. 2025;55(9):e70088. DOI: 10.1111/eci.70088
5.
TakahashiT.Urologists and pathologists in prostate cancer screening. Virchows Arch. Epub ahead of print September 2024. DOI: 10.1007/s00428-024-03929-y
6.
LucassenAMcCartneyMSullivanR.Prostate cancer: polygenic risk scores have not shown clinical benefit. BMJ. 2025;389:r1179. DOI: 10.1136/bmj.r1179
7.
BeyerKLeenenRVenderbosLDF, et al. The PRAISE-U consortium. Health policy for prostate cancer early detection in the European Union and the impact of opportunistic screening: PRAISE-U consortium. J Pers Med. 2024;14(1):84. DOI: 10.3390/jpm14010084
8.
ZahlPHGotzschePCMahlenJ.Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol. 2011;12(12):1118–24. DOI: 10.1016/S1470-2045(11)70250-9
BretthauerMWieszczyPLobergM, et al. Estimated lifetime gained with cancer screening tests: a meta-analysis of randomized clinical trials. JAMA Intern Med. 2023;183(11):1196–203. DOI: 10.1001/jamainternmed.2023.3798
